News
MGTX
9.40
-5.53%
-0.55
MeiraGTx Holdings Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
MeiraGTx Holdings Price Target Raised to $25.00/Share From $24.00 by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on MeiraGTx Holdings, Raises Price Target to $25
Benzinga · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Meiragtx Holdings (MGTX), CalciMedica (CALC)
TipRanks · 1d ago
MeiraGTx files Form 3 for Chief Development Officer Penny Renee Fleck
PUBT · 1d ago
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Cardiff Oncology (CRDF) and Meiragtx Holdings (MGTX)
TipRanks · 1d ago
MeiraGTx grants CDO Penny Fleck 100,000 options, 100,000 RSUs as inducement award
PUBT · 1d ago
MEIRAGTX ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
MeiraGTx reports Q1 EPS (57c), consensus (45c)
TipRanks · 1d ago
MeiraGTx Hldgs Q1 EPS $(0.57) Misses $(0.44) Estimate, Sales $293.000K Miss $13.913M Estimate
Benzinga · 2d ago
Gene therapy firm MeiraGTx Q1 revenue drops, net loss widens
Reuters · 2d ago
*MeiraGTx Holdings 1Q Rev $293,000 >MGTX
Dow Jones · 2d ago
*MeiraGTx Holdings 1Q Loss $46.3M >MGTX
Dow Jones · 2d ago
*MeiraGTx Holdings 1Q Loss/Shr 57c >MGTX
Dow Jones · 2d ago
MeiraGTx GAAP EPS of -$0.57 misses by $0.18, revenue of $0.29M
Seeking Alpha · 2d ago
BRIEF-MeiraGTx Q1 Revenue USD 293 Thousand Vs. IBES Estimate USD 19.9 Million
Reuters · 2d ago
MEIRAGTX REPORTS FIRST QUARTER 2026 FINANCIAL AND OPERATIONAL RESULTS
Reuters · 2d ago
Press Release: MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Dow Jones · 2d ago
FDA Commissioner Marty Makary resigns
TipRanks · 3d ago
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
TipRanks · 3d ago
More
Webull provides a variety of real-time MGTX stock news. You can receive the latest news about Meiragtx Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About MGTX
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.